Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pyridostigmine kinetics with and without renal function

R Cronnelly, D R Stanski, R D Miller

    Clinical Pharmacology and Therapeutics
    |July 1, 1980
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Drug effects on the CVS in conscious rats: separating cardiac output into heart rate and stroke volume using PKPD modelling.

    British journal of pharmacology·2014
    Same author

    Pharmacodynamic measurements of methyl nicotinate percutaneous absorption.

    Pharmaceutical research·2013
    Same author

    PKPD modelling of the interrelationship between mean arterial BP, cardiac output and total peripheral resistance in conscious rats.

    British journal of pharmacology·2013
    Same author

    Individualized dosing with anesthetic agents.

    Clinical pharmacology and therapeutics·2012
    Same author

    A new Bayesian method to forecast and fine tune individual hemodialysis dose.

    Hemodialysis international. International Symposium on Home Hemodialysis·2009
    Same author

    Pharmacokinetics and pharmacodynamics of intravenously administered anesthetic drugs: concepts and lessons for drug development.

    Clinical pharmacology and therapeutics·2008
    Same journal

    Clinical Characterization of Enzyme and Transporter Precipitants to Evaluate Drug-Drug Interactions for Orforglipron, a Small Molecule Glucagon-Like Peptide-1 Receptor Agonist.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Symposium Report: Stakeholders' Perspectives on Phase 1 Trials in Japanese Prior to Multi-Regional Clinical Trials and Future Pathways.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Resolving CYP2D6 Structural Complexity with Long-Read Sequencing: Implications for Tamoxifen Precision Dosing in Thai Breast Cancer Patients.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Identification of a Functional CYP2C8 Variant Allele that Alters Splicing, Reduces Protein Expression, and Increases Drug Exposure.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Risk of Hyperkalemia in Patients with Heart Failure Treated with Spironolactone in Combination with Sacubitril/Valsartan vs. Renin-Angiotensin System Inhibitors.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Composite Endpoints in Contemporary Cardiovascular Trials: Trends in Phase 3 Trials and Key Issues in Regulatory Review.

    Clinical pharmacology and therapeutics·2026
    See all related articles

    Renal function significantly impacts pyridostigmine clearance, with anephric patients showing reduced clearance and longer elimination half-lives. Kidney function accounts for 75% of pyridostigmine elimination.

    Area of Science:

    • Pharmacokinetics
    • Nephrology
    • Anesthesiology

    Background:

    • Pyridostigmine is used to reverse neuromuscular blockade.
    • Understanding its pharmacokinetics is crucial for safe clinical use, especially in patients with impaired renal function.

    Purpose of the Study:

    • To investigate pyridostigmine pharmacokinetics in anesthetized patients with normal, impaired, or absent renal function.
    • To determine the role of renal function in pyridostigmine clearance.

    Main Methods:

    • Serum pyridostigmine levels were measured using gas-liquid chromatography.
    • Data were analyzed using a two-compartment kinetic model.
    • Patients were categorized based on renal function: normal, post-renal transplant, and anephric.

    Related Experiment Videos

    Main Results:

    • Pyridostigmine kinetics in patients with normal renal function and those post-renal transplant were similar.
    • In anephric patients, the elimination half-life of pyridostigmine increased significantly (112 min to 379 min).
    • Serum clearance of pyridostigmine decreased substantially in anephric patients (9 ml/kg/min to 2 ml/kg/min).

    Conclusions:

    • Renal function is a major determinant of pyridostigmine clearance, accounting for approximately 75%.
    • Dosage adjustments may be necessary for pyridostigmine in patients with significantly impaired or absent renal function.